Published in final edited form as:

J Neurovirol. 2008 ; 14(6): 536–549. doi:10.1080/13550280802378880.

Neurobehavioral effects of HIV infection among former plasma donors in rural China:

Neurobehavioral effects of HIV in rural China

Robert K. Heaton¹, Lucette A. Cysique¹, Hua Jin^{1,2}, Chuan Shi³, Xin Yu³, Scott Letendre¹, Donald R. Franklin Jr¹, Christopher Ake¹, Ofilio Vigil¹, J. Hampton Atkinson¹, Thomas D. Marcotte¹, Igor Grant¹, and Zunyou Wu [on behalf of the HNRC group]⁴

¹HIV Neurobehavioral Research Center (HNRC), Department of Psychiatry, University of California at San Diego, San Diego, California.

²VA San Diego Health Care System, San Diego, California.

³Institute of Mental Health, Peking University, Beijing, China.

⁴National Center for AIDS/STD Control & Prevention (NCAIDS), Beijing, China.

Abstract

The HIV epidemic in China has expanded rapidly in recent years, but little is known about the prevalence and features of HIV Associated Neurocognitive Disorders (HANDs) in this part of the world. We administered a comprehensive Western neuropsychological (NP) test battery to 203 HIV+ and 198 HIV-former plasma donors in the rural area of Anhui province. We found that 26% in the HIV- sample, and 46% in the HIV+ sample were infected with HCV, which can also have CNS effects. To classify NP impairment, we developed demographically corrected test norms based upon individuals free of both infections (N=141). Using a global summary score, NP impairment was found in 34.2% of the HIV mono-infected group and 39.7% of the co-infected group, as compared to 12.7% of the uninfected controls ($p<.001$). HIV+ participants with AIDS were more likely to be impaired (43%) than non-AIDS individuals (29%, $p<.05$). Lastly, when all infection groups were combined, participants with NP impairment reported more cognitive complaints ($p<.01$) and increased dependence in everyday functioning ($p=.01$). In sum, NP impairment in this large rural Chinese sample was associated with both HIV and HCV infections, and the impairment's prevalence, severity, and pattern were similar to those reported by Western studies. Clinical significance of NP impairment in this population is suggested by the participants'

Correspondence: **Robert K. Heaton**: Department of Psychiatry, University of California San Diego, 9500 Gilman Drive #0603, La Jolla, California, 92093-0603. Phone 858-534-4044; Fax: 858-534-7653. Email: rheaton@ucsd.edu.

*The San Diego HIV Neurobehavioral Research Center [HNRC] group is affiliated with the University of California, San Diego, the Naval Hospital, San Diego, and the Veterans Affairs San Diego Healthcare System, and includes: Director: Igor Grant, M.D.; Co-Directors: J. Hampton Atkinson, M.D., Ronald J. Ellis, M.D., Ph.D., and J. Allen McCutchan, M.D.; Center Manager: Thomas D. Marcotte, Ph.D.; Naval Hospital San Diego: Braden R. Hale, M.D., M.P.H. (P.I.); Neuromedical Component: Ronald J. Ellis, M.D., Ph.D. (P.I.), J. Allen McCutchan, M.D., Scott Letendre, M.D., Edmund Capparelli, Pharm.D., Rachel Schrier, Ph.D.; Neuroimaging Component: Terry Jernigan, Ph.D. (P.I.), Christine Fennema-Notestine, Ph.D., Sarah L., Archibald, M.A., John Hesselink, M.D., Jacopo Anness, Ph.D., Michael J. Taylor, Ph.D.; Neurobiology Component: Eliezer Masliah, M.D. (P.I.), Ian Everall, FRCPsych., FRCPPath., Ph.D., Cristian Achim, M.D., Ph.D.; Neurovirology Component: Douglas Richman, M.D., (P.I.), David M. Smith, M.D.; International Component: J. Allen McCutchan, M.D., (P.I.); Developmental Component: Ian Everall, FRCPsych., FRCPPath., Ph.D. (P.I.), Stuart Lipton, M.D., Ph.D.; Clinical Trials Component: J. Allen McCutchan, M.D., J. Hampton Atkinson, M.D., Ronald J. Ellis, M.D., Ph.D., Scott Letendre, M.D.; Participant Accrual and Retention Unit: J. Hampton Atkinson, M.D. (P.I.), Rodney von Jaeger, M.P.H.; Data Management Unit: Anthony C. Gamst, Ph.D. (P.I.), Clint Cushman, B.A., (Data Systems Manager), Daniel R. Masys, M.D. (Senior Consultant); Statistics Unit: Ian Abramson, Ph.D. (P.I.), Christopher Ake, Ph.D., Florin Vaida, Ph.D.

The views expressed in this article are those of the authors and do not reflect the official policy or position of the Department of the Navy, Department of Defense, nor the United States Government.

reports of reduced everyday functioning. These findings indicate that HAND is likely to be an important feature of HIV infection in developing countries, underscoring the need for international efforts to develop CNS relevant treatments.

Keywords

HIV; HCV; neurocognitive disorders; China

Introduction

The HIV epidemic in China is being closely monitored by the Chinese government, together with the World Health Organization (WHO) and UNAIDS. Their most recent reports estimated that 700,000 mainland Chinese people were living with HIV at the end of 2007, and that during that year there were around 50,000 new infections and 20,000 AIDS deaths (State Council AIDS Working Committee Office and United Nations Theme Group on HIV/AIDS in China, 2007).

In Western countries the initial HIV epidemic tended to be concentrated in urban areas within the gay male population. By contrast, in China the HIV epidemic began in rural areas in association with blood product collection and use, before spreading to urban injection drug users (IDUs), among whom it has reached very high rates of infection in some areas (up to 44% - Zhao et al, 2006). The epidemic among Chinese former plasma donors (FPDs), on which this current study is focused, has been centered in agrarian provinces such as Anhui, Hebei, Henan, Hubei and Shanxi (Cohen, 2004). In these areas prior to the mid 1990s, a large number of poorly regulated commercial plasma collection companies were in operation, some using non-sterile techniques. Residents would supplement their small farming incomes by selling their plasma, in some cases very often, unknowingly placing themselves at risk for exposure to HIV and other blood borne pathogens. In the mid 1990s the Chinese government imposed strict regulations to prevent further spread of HIV in this way.

Estimates of future infections are difficult, but UNAIDS and other organizations have predicted that by 2010, there could be a generalized epidemic with between ten and twenty million HIV-infected Chinese (UNAIDS, 2006). Because China is the most populous country on earth, with 1.3 billion people, the growth of the HIV epidemic there is cause for considerable concern.

It is well documented that HIV enters the central nervous system (CNS) early after infection and can be associated with neurocognitive impairment in up to 50% of individuals with AIDS (Heaton et al, 1995; Antinori et al, 2007). However, almost all of this data comes from studies conducted in the U.S., Europe and Australia. Little is known about the prevalence and nature of neurobehavioral complications of HIV in developing areas of the world, including China.

In the U.S., research prior to availability of Highly Active Antiretroviral Treatment (HAART) demonstrated that presence of neuropsychological (NP) impairment in HIV infected persons conferred an increased risk early mortality, above and beyond what could be predicted from medical indices of disease progression (Mayeux et al, 1993; Ellis et al, 1997). It is unclear whether NP impairment still produces worse medical outcomes in the context of HAART, but there is considerable evidence that even mild NP impairment is associated with reduced vocational functioning and other difficulties with cognitive aspects of everyday functioning: medication management, driving, and Instrumental Activities of Daily Living (IADLs;

Carter et al, 2003; Heaton et al, 2004a; Hinkin et al, 2004; Marcotte et al, 2006). It is unknown whether any NP deficits that may be observed among HIV infected Chinese farmers would have the same relevance in their lives, or if such deficits could even be noticed by the patients and others around them.

An even more fundamental question is whether Western NP tests will be valid in developing countries, where the people have very different educational, cultural, and linguistic backgrounds from those in the U.S., Europe and Australia. Previous studies in developing countries have been able to use Western NP tests, but estimates of prevalence of HIV-associated neurocognitive disorders (HANDs) from these studies have varied widely. One impediment to reliable estimates of HANDs across studies is the fact that normative data from HIV-uninfected (HIV-) samples matched for age, education, gender, and disease risk factors, were not typically available. This means that some of the “impairment” interpreted as being due to HIV could reflect variation due to other factors. Other reasons for inconsistent findings include use of more or less conservative definitions of NP impairment, differences in the NP tests themselves, and the degree to which investigators have considered comorbid medical and psychiatric conditions that are common in the various populations being studied (e.g., histories of substance use disorders or significant head trauma, other infectious diseases such as malaria, tuberculosis, syphilis and hepatitis C virus - HCV).

So far, the feasibility of cross-cultural NP investigations of HIV effects has been demonstrated best by the WHO Neuropsychiatric AIDS Study Trial (Maj et al, 1994a, 1994b). This study examined the NP status of HIV-, HIV+ asymptomatic and HIV+ symptomatic participants in five countries: Germany, Brazil, Kenya, Zaire and Thailand. A Western NP test battery covering multiple ability domains was translated and successfully administered in the five relevant languages. An increased prevalence of NP impairment was seen among medically symptomatic HIV+ groups (versus their respective HIV- comparison groups) in all sites, whereas asymptomatic participants showed increased rates of impairment in Brazil and Zaire, and in the lowest educated subgroups in Kenya.

More recently, two NP studies of HIV+ groups in sub-Saharan Africa have found very inconsistent results. Robertson et al. (2007) administered the International HIV Dementia Scale (IHDS) and an NP battery covering five ability areas to 110 HIV+ and 100 HIV- adults in Uganda (see also Sacktor et al, 2005; 2006 and Wong et al, 2007 for additional findings with these cohorts). Forty-nine (44.5%) of the infected participants had histories of some ART. Although efforts were made to recruit demographically comparable groups, the HIV- participants were younger (mean 27.5 years versus 36.7 for HIV+), more highly educated (mean 12.1 years, versus 9.1 years for HIV+) and contained fewer females (40% versus 70% for HIV+). Using ANCOVAs with education covaried, the HIV+ group did significantly worse on a mean NP z-score and on all individual tests except for Timed Gait and Grooved Pegboard. Contrasting results were reported by Clifford et al. (2007), who administered the IHDS, and Category Fluency (animals), Timed Gait, Grooved Pegboard and Finger Tapping tests to 73 HIV+ (ART naïve) and 87 HIV- patients in an Ethiopian outpatient clinic. These groups were well matched demographically, and their test performances differed significantly only on Finger Tapping. Clifford and colleagues acknowledged that their test battery was limited, but suggested that their negative results “may be more reliable than studies from other developing countries” (p.70) because their HIV+ and HIV- participants come from the same clinic population, with the same demographic characteristics. Another possibility mentioned by these authors is that the HIV subtype that predominates in Ethiopia (clade C) may have less neurotropism than clade B (predominant in North America, Europe and Australia) and / or clades more predominant in Uganda (clades A & D). However, there is preliminary evidence of NP and

electroencephalographic abnormalities being associated with clade C infection in India (Riedel et al, 2006; Sinha & Satishchandra, 2003; Yephthomi et al, 2006).

Finally, Cysique et al. (2007a) recently reported a small study comparing NP effects of HIV infection (clade B) in China and the U.S. An NP test battery that has been used in large multi-site studies in the U.S. was translated and adapted slightly for cultural relevance to the Chinese population, and was administered to 28 HIV+ and 23 demographically similar HIV – controls in China, as well as to 39 HIV+ and 31 HIV– controls in the U.S.. The test battery was well understood and tolerated by the Chinese participants. Importantly, a comparably robust HIV effect on NP performance was found in the two countries. This served as a pilot study for the current investigation of HIV infection among FPDs in Anhui province. There was no overlap in the samples used in the two studies.

The current study is a first large scale attempt at providing estimates of the prevalence and nature of HANDs within a major risk group in China (FPDs), and at exploring the possible relevance of such impairments to participants' everyday functioning. All participants (both HIV– and HIV+) were FPDs with no other known risk for HIV infection. In addition to selecting large, demographically comparable samples of HIV+ and HIV– participants from the same population and risk group, our study design involved systematically examining effects of comorbid medical and psychiatric conditions considered relevant to this population. Also, we used data from the uninfected controls to develop demographically corrected, Chinese NP norms, which would enable more accurate classification of acquired NP impairments in individual participants. Our hypotheses were: 1). more NP impairment would be seen in the HIV+ group than in the HIV– comparison group; 2). Within the HIV+ group, increased NP impairment would be associated with a history of severe immunosuppression (as indexed by the nadir CD4 cell count) and/or AIDS defining illness; and 3). NP impairment would be associated with reports of decreased functioning in daily life (i.e., more cognitive complaints, lower employment rates, decreased independence in instrumental activities of daily living).

Methods

This report concerns baseline findings of a five year longitudinal project to examine neurobehavioral effects of HIV infection in China. The study was approved by the Institutional Review Boards (IRBs) from the China CDC/National Center for AIDS (NCAIDS), as well as the Peking University and the University of California at San Diego (UCSD).

Participants

In December 2005, trained study recruiters in the Fuyang city CDC in Anhui province started the screening of FPDs for the current study. All participants received the HIV Quick Test (OraSure Technologies, Inc, Bethlehem, PA) to confirm their HIV status before enrollment. By June 2006, 198 HIV– and 203 HIV+ individuals had been enrolled. Written informed consent was obtained from the participants after the research procedure had been fully explained to them. Participants were reimbursed 80 Chinese Yuan (\$10–11) for their time. All participants shared the infection risk of being FPDs and only one participant in the HIV+ group reported homosexual contact as an additional risk factor. Individuals with a known history of non-HIV related neuromedical factors that might potentially cause impairment of neurocognitive function were excluded from the study. These exclusion criteria consisted of head injury with unconsciousness greater than 30 minutes, and any known, non HIV related neurological disorders (e.g., epilepsy, stroke), psychotic disorders (schizophrenia and bipolar disorder) and potentially significant levels of current substance use, defined as more than two alcoholic drinks per day over the past 30 days, or use of any

illegal drugs in the past 30 days. Infection with the Hepatitis C Virus (HCV) was assessed using HCV antibody testing of study blood samples, but was not an exclusion criterion because (a) participants were not aware of their HCV serostatus, and (b) relationship between HCV and NP impairment in China was unknown.

Procedure

In addition to providing demographic and medical history information, every participant underwent comprehensive neurocognitive and neuromedical evaluations, and a structured psychiatric examination, as well as an assessment of daily functioning. This report focuses on the neurocognitive results and their relation to traditional HIV biomarkers, HCV seropositivity, depression, lifetime histories of substance use disorders, and self-reports of increased difficulties in everyday functioning.

In order to ensure standardization of all test administration, examiners (physicians and nurses from an Anhui local psychiatric hospital) had two weeks of training done by a previously trained and certified Chinese psychiatrist (CS) and a team from the U.S. (RKH, HJ, DF). There were separate training teams for the neurobehavioral, neuromedical, and psychiatric modules of the battery, with at least one bilingual member on each training team to facilitate discussion. During the two-week training session in Beijing, each test, exam, or interview was demonstrated, and its purpose and administration nuances were discussed. Several rounds of “mock testing” were conducted. Certification sessions subsequently took place using staff or patient volunteers from the hospital as test subjects. All certifications were done in Chinese.

Quality assurance reviews were conducted on test forms on the first 40 visits from Anhui, to ensure that drift had not occurred between training and study start. Copies of the entire battery were sent to the U.S. and reviewed for administration and scoring accuracy, form completion, and overall quality of data. All queries and data changes were sent to the China team for correction of the raw data as well as correction of the data entry. After the first 40 visits, 15% of all visits were similarly reviewed. As before, all queries and data changes were made to both the raw data and the database.

Details of the NP battery selection and adaptation for use in China are provided in Cysique et al. (2007a). The NP battery in Mandarin was administered by trained examiners in the local Fuyang dialect, which uses the same written form as the Mandarin, but sometimes is pronounced differently. The NP test battery was composed of 18 individual NP measures which assessed 7 ability areas that have been found to be affected by HANDs in Western countries (see Table 3 for listing). This battery includes tests widely used to study HIV infection in the U.S. (Carey et al, 2004; Woods et al, 2004), Europe (Tozzi et al, 2007), Australia (Cysique et al, 2006) and in multi-national studies (Maj et al, 1994).

To explore the clinical significance of any NP impairment, we assessed cognitive complaints, degree of independence in activities of daily living, and employment status using Chinese translations of standard English instruments. Subjective neurocognitive complaints were assessed using the Patient's Assessment of Own Functioning Inventory (PAOFI; Chelune, Heaton & Lehman, 1986). The PAOFI includes 33 items on which participants rate themselves as having or not having neurobehavioral difficulties in their everyday lives, using a six-point scale: almost never, very infrequently, once in a while, fairly often, very often and almost always, in domains of memory, language and communication, sensory-perceptual and motor skills, and higher level cognitive functions. The score used is the sum of items on which the participants reported experiencing difficulties as either “fairly often”, “very often” or “almost always” (Chelune, Heaton & Lehman, 1986). Employment status was derived from the extended demographic interview

which collected information on whether the participant is currently working, as well as type of employment, and income. The modified version of the Lawton & Brody IADL scale was used to assess independence in activities of daily living (Heaton et al, 2004a).

In order to assess for major depressive disorder (MDD) and substance use disorders, participants were administered those modules of the Chinese version of the World Mental Health Composite International Diagnostic Interview (WMH-CIDI, Kessler et al, 2004a). This lay-administered and fully-structured instrument yields diagnoses consistent with those derived by clinician interviewers using the Structured Clinical Interview for DSM-IV (First, Spitzer, Gibbon, & Williams, 1996; Kessler et al, 2004b). Participants also completed the Beck Depression Inventory-II (BDI-II; Beck, Steer, & Brown, 1996a, b). The BDI-II is a 21-item self-report measure that rates severity of depressive symptoms during the past week, addressing somatic (e.g., weight loss, fatigue) and non-somatic (e.g., suicidal ideation, feelings of guilt) depressive symptoms – higher scores indicate greater depressive symptomatology.

Data Analysis

In order to classify NP impairment in individual participants, we developed demographically corrected norms on the NP tests using data from individuals free of HIV as well as Hepatitis C infection (N=141). Preliminary analyses revealed that HCV+ status was associated with NP impairment in this cohort. Statistical methods used to develop demographically corrected norms are detailed in Heaton et al. (2004b), and include the following steps: First, raw scores on the individual tests were placed on a common metric (normally distributed scaled scores which have a mean of 10 and a standard deviation of 3 in the Chinese normative group). The scaled scores were then converted into T-scores: the demographic data (age, education and gender) were used to generate fractional polynomial regression equations to optimally predict the scaled scores. To determine the optimal fractional polynomial equation, the method of Royston and Altman (1994) was employed using the statistical package StataCorp (2003 - Stata Statistical Software: Release 8.0. College Station, TX: Stata Corporation). The residuals from optimal regression equations were then converted to T-scores with a mean of 50 and a standard deviation of 10.

In addition to computing mean T-scores for each NP test measure, a Global mean T and mean T-scores for the seven ability domains were computed (see listing in Table 3). Also, the Global Deficit Score (GDS) method was used for classification of overall impairment status on the battery (see Carey et al, 2004 and Heaton et al, 2004b, for detailed description). Briefly, demographically corrected T-scores were converted to deficit scores according to the following criteria: $T > 39 = 0$ (normal), $39 \geq T \geq 35 = 1$ (mild impairment), $34 \geq T \geq 30 = 2$ (mild to moderate impairment), $29 \geq T \geq 25 = 3$ (moderate impairment), $24 \geq T \geq 20 = 4$ (moderate to severe impairment), $T < 20 = 5$ (severe impairment). Deficit scores were summed across the test battery and then divided by the number of individual measures to compute the GDS. The GDS can be analyzed as a continuous variable indicating number and severity of neurobehavioral deficits across the entire test battery, or as a cut-off of ≥ 0.50 that can be used to classify overall NP impairment (Carey et al, 2004; Heaton et al, 2004b). Comparisons between groups were made using Chi-square tests, Fisher's Exact Tests, t-Tests and ANOVAs as appropriate. To infer meaningful effects of relevant variables, Cohen's d effect sizes also were computed for group comparisons.

Results

FPD participants' demographic, clinical and laboratory characteristics

Importantly, 25.6% of the HIV- sample and 46.3% in the HIV+ sample tested positive for HCV ($p<.0001$). Demographic data are therefore presented in Table 1 for the four subject groups: controls; HIV mono-infected; HCV mono-infected and co-infected samples. The four groups were comparable with respect to age and education while female gender was more prevalent in the HCV mono-infected group when compared to controls. All participants spoke the regional language (Fuyang Chinese dialect) and the proportion of persons fluent in formal Mandarin did not differ between groups. Virtually all participants belong to the Han ethnicity and all grew up and continued to reside in this rural area of Anhui province. The family size in the participants' households did not differ between the groups. All participants were either married or widowed, but the HIV mono-infected participants were more likely to be widowed when compared to controls. Lastly, we found that HIV mono-infected and co-infected individuals made on average many more plasma donations compared controls and HCV mono-infected individuals (see Table 1).

Psychiatric assessments revealed that none of our participants had lifetime histories of substance (other than alcohol) use disorders. Lifetime prevalence for alcohol use disorders differed significantly between controls ($n=5$; 3.5%) and all other groups: HIV mono-infected group ($n=19$, 17.6%; $p=.0002$); HCV mono-infected group ($n=6$, 11.7%; $p=.05$) and co-infected group ($n=10$, 10.7%; $p=.03$). A small minority of our participants ($<1\%$) met criteria for an alcohol use disorder in the last 30 days: one HIV mono-infected participant, one HCV mono-infected participant and 1 co-infected participant (these three participants did not report drinking more than two alcoholic drinks per day over the past 30 days at the screening enrollment, but gave more candid reports during the subsequent diagnostic interview). Only two controls and three HIV mono-infected individuals and one co-infected individual met criteria for current major depressive disorder (MDD). Seven controls (4.9%) and three HCV mono-infected (5.8%) met criteria for lifetime MDD, and this was significantly different from 15 HIV mono-infected (13.9%; $p=.02$) and 13 co-infected (14%; $p=.02$) who met this criteria. Also, the HIV mono-infected group (10.5 ± 10.4 ; $p=.002$) and the co-infected group (12.1 ± 12.3 ; $p<.0001$) reported significantly more currently depressed mood on the BDI-II but not the HCV mono-infected (8.9 ± 10.8) as compared to controls (5.9 ± 9.2).

Table 2 summarizes the clinical and laboratory characteristics of the HIV mono-infected and co-infected groups. AIDS was more common in the mono-infected sample as compared to the co-infected sample, but most of these were so classified because of a history of severe immunosuppression (i.e., only 12% had a history of AIDS-defining illness in the HIV mono-infected group compared to 18.5% in the co-infected group). Sixty percent in the HIV mono-infected group and 47% in the co-infected group were prescribed antiretroviral treatment by their local clinicians for an average of 97 days. Almost all treated participants reported being strictly adherent to their medication regimens and this did not differ between mono-infected and co-infected individuals.

NP test results

All 401 participants successfully completed the NP battery and the examiners rated their cooperation and effort as adequate in all cases. Table 3 summarizes raw score results on the individual NP test measures, and also indicates effect sizes obtained comparing the infected groups to the uninfected controls. Small to medium effect sizes were obtained for HIV mono-infection and HIV/HCV co-infection on all measures except the Wisconsin Card Sorting Test (WCST). By contrast, HCV mono-infection was associated with small effect

sizes on only 11 of the 18 measures. (Since the WCST demonstrated no sensitivity to any type of infection in this study, it was not included in subsequent analyses of summary scores on the NP ability domains and the total test battery.)

Mean T-scores for the total test battery and the seven ability domains all showed significant overall group effects ($p < .001$). Figure 1 displays the effect sizes (Cohen's d) for comparisons of individual infection groups versus controls. On the global mean T-score, the co-infected group and HIV mono-infected group showed medium to large effect sizes ($d = .83$ and $.72$, respectively), whereas the HCV mono-infected group showed a small to medium difference ($d = .45$).

Figure 1 and Table 3 may be considered together to explore pattern differences on the seven ability domains. Both HIV infected groups showed their largest impairments on measures of processing speed, whereas the HCV mono-infected group showed small and inconsistent deficits on tests within this domain. All three infected groups showed consistent impairments on measures of learning, memory (delayed recall) and motor skills. Suggestive of some additive effects of HIV and HCV, the co-infected group showed more impairment than either mono-infected group on tests of attention/working memory, learning and verbal fluency.

Finally, using the standard GDS cut-off of 0.50 to classify individual participants' NP impairment status, rates of impairment were 12.7% in controls, 34.2% for the HIV mono-infected group, 37.2% in the HCV mono-infected group, and 39.7% in the co-infected group (X^2 ($df=3$)=26.8, $p < .0001$). Most of this impairment was in the mild range (53.7% of impaired individuals in the combined infected groups; $GDS = 0.50-0.99$). According to recently updated research definitions of HANDs (Antinori et al, 2007), only nine (4.4%) of HIV infected participants in this study met NP criteria for diagnosis of HIV-associated dementia (i.e., at least moderate NP impairment involving two or more ability domains); all but one of these had AIDS.

HIV disease history and NP impairment

Blood draw could not be obtained for two HIV+ and six HIV- individuals, so analyses of relationships between current laboratory values and NP status excluded them. As noted above, the large majority of our participants with AIDS were prescribed HAART, which would be expected to suppress HIV plasma viral load and improve immuno-competence. We therefore anticipated that NP status would be more related to nadir CD4 cell count (part of the CDC definition of AIDS) than to current CD4 count and current plasma viral load. In fact, HIV+ participants who were NP-impaired ($n=74$) had significantly lower nadir CD4 counts than those ($n=125$) who were NP-normal (respective means= 214.4 ± 143.9 vs. 274.8 ± 161.1 , $t(197)=2.7$, $p=.007$). Also HIV+ persons with AIDS (defined mostly due to a history of severe immuno-suppression; see Table 2) had a higher rate of NP impairment than those without AIDS (43.0% vs. 29.2%; $X^2(df=1)=4.0$, $p<.05$). This difference was not attributable to co-infection with HCV, because there was a higher prevalence of AIDS in the mono-infected HIV+ group (65.7% vs. 45.2% for co-infected group) and AIDS was associated with higher rates of impairment in both HIV+ groups. By contrast, NP impairment was not associated with worse current CD4 cell counts (334.7 ± 229.8 in NP-impaired subgroup, vs. 358.6 ± 184.3 in NP-normal subgroup; $t(199)=0.7$, $p=.44$). Similarly, plasma HIV RNA was detectable in 60.8% of the NP-impaired subgroup, versus 68% in the unimpaired subgroup; for the infected participants with detectable viral load, the mean Log_{10} HIV RNA was comparable for the impaired and unimpaired subgroups (3.9 ± 0.8 vs. 4.1 ± 0.8 ; $t(130) = 0.8$, $p=.38$).

Association between NP impairment, alcohol use disorder and depression

As noted above, although virtually no participants in this study met criteria for current substance use disorders, 14.3% of the HIV+ group versus 5.6% of the HIV- individuals met criteria for an alcohol use disorder in their lifetime. Within the HIV+ group, those with histories of lifetime alcohol use disorders (n=29) evidenced a lower rate of NP impairment than the large majority who had no history of abuse or dependence (20.6% vs. 39.6%; $p=.05$). Also, of the three participants who initially reported minimal current alcohol use but later gave different information that met criteria for alcohol use disorders during the previous 30 days, the two HIV+ individuals were NP-normal whereas the HCV mono-infected person was NP-impaired. Lastly, the 28 HIV+ participants who met criteria for lifetime MDD had no more NP impairment than their non-depressed counterparts (32.1% vs. 37.7%). Although correlations were statistically significant because of the large sample size, the amounts of shared variance between current depressive symptoms (BDI-II) and NP functioning within the HIV+ group are very small ($R^2 = .03$ for both global mean T-scores and GDS). Finally, 54 (26.6%) of the HIV+ sample reported clinically significant current levels of depressed mood ($\text{BDI-II} \geq 17$; Beck et al, 1996a), but their rate of NP impairment was not significantly greater than that of the non-depressed HIV+ participants (44.4% vs. 34.2%; $p=.18$).

Impact of infection and NP-impairment on everyday functioning

Table 4 summarizes infection group differences on indicators of impaired (reduced) everyday functioning. Compared to uninfected controls, all three infection groups had more cognitive complaints. Only the HIV/HCV co-infected group reported increased dependence on others in performing IADLs, whereas both HIV infected groups reported decreased current employment and fewer months worked during last year.

In the combined infection group (N= 254), 94 were NP-impaired and 164 were NP-normal. The impaired subgroup reported significantly more cognitive complaints (6.73 ± 6.46 vs. 4.33 ± 5.32 ; $t(252)=-3.0$, $p=.003$), as well as more dependence in IADLs (0.71 ± 1.58 vs. 0.30 ± 1.04 ; $t(252)=-2.3$, $p=.03$). However, NP impairment was not significantly related to employment status (77.7% employed in the NP-impaired vs. 85% for NP-normal). The IADLs that were most often impacted among NP-impaired, infected individuals involved financial management, shopping, housekeeping and cooking.

Discussion

There are three main findings in this study. First, we demonstrated that the NP assessment methods developed and widely used in the U.S. could be used effectively within the context of rural China, with individuals having very low levels of education compared to U.S. standards. Secondly, we found that increased rates of NP impairment in this large rural Chinese sample of former plasma donors were associated with both HIV and HCV infections. Both HIV-associated and HCV-associated NP impairment showed robust effect sizes, comparable to what has been observed in U.S. cohorts. Thirdly, clinical significance of NP impairment in this population is suggested by the participants' reports of reduced everyday functioning.

All 401 Chinese participants were able to understand and follow the NP test instructions, and obtained what appeared to be valid results. It should be noted that careful translation and piloting of test instruments and the thorough training of the examiners were both important steps in the adaptation and deployment of our NP battery (see Methods & Cysique et al, 2007a for more details). As expected from prior results with Western HIV+ and HIV- cohorts, we found that almost all individual tests in this battery showed some sensitivity to

HIV effects in the Chinese FPDs. The single exception was the WCST, which showed no sensitivity to HIV and/or HCV infections in this population. The reason for this is unclear, but it could be that the cultural and/or educational backgrounds of our participants gave them insufficient familiarity with the WCST's stimuli, categorization rules, or the need to repeatedly change rules of responding throughout the test. Regardless of the reason, it appears that this particular test has little or no value in assessing rural Chinese people such as those in the current study.

Clifford et al. (2007) has suggested that some of the reported HIV effect on NP functioning in developing countries may have been biased by the use of HIV- comparison groups that differ from the HIV+ groups in important demographic and background features (e.g., different HIV risk groups). However, the HIV+ and HIV- samples in this study are from the same risk group (FPDs) and have virtually identical demographic and background characteristics (Table 1). Nevertheless, we found robust HIV effects on NP function that are similar to those historically seen in Western countries.

To our knowledge this is the first effort in HIV research within developing countries to use demographically corrected NP norms, based upon results of a large, uninfected group with very similar backgrounds. This permits more accurate classification of acquired HIV-related impairment in individual cases, and arguably provides the best estimates prevalence of HIV-related of impairment. The association of impairment status with biological variables in this study (nadir CD4 and co-infection with HCV) supports the validity of the tests and the norms in this population. On the other hand, generalizability of these norms to populations in other developing countries is uncertain.

The pattern of NP performance in HIV mono-infected individuals is consistent with what has been observed in U.S. cohorts (Heaton et al, 1995), with predominant deficits in processing speed, learning, motor functions and some aspects of executive functions. Also as observed in the U.S., AIDS status was associated with worse overall rates of impairment when compared to non-AIDS participants. The severity of HIV-associated NP impairment observed in this population also is similar to what is seen in Western countries in the era of HAART: almost all (66 of 75) NP-impaired HIV+ participants had GDSs in the mild to moderate range. Only 4% of the total HIV+ group had NP impairment that was severe enough to be consistent with a diagnosis of HIV-associated dementia (Antinori et al, 2007).

Although a majority (56.6%) of our HIV+ FPDs met CDC criteria for an AIDS diagnosis, only 15% had any history of an AIDS defining illness. Most of the AIDS diagnoses occurred because of a prior history of severe immuno-suppression (nadir CD4 $\leq$ 200) which then led to their being prescribed modern and effective antiretroviral treatments. This, then, was a relatively healthy HIV+ cohort from the point of view of the proportion of individuals with a history of symptomatic disease. Compared to a large U.S. HIV+ cohort having almost identical rates of AIDS defining illness (Heaton et al, 1995), the current NP methodology (i.e., GDS approach) yielded very similar rates of HIV-associated NP impairment (34.2% in our mono-infected HIV+ group, vs. 31.6% in the U.S. group).

As in studies conducted in Western countries (Letendre et al, 2004; Cysique et al, 2006; Tozzi et al, 2007), we found that in a mixed group of untreated and HAART-treated HIV+ participants, nadir CD4 was associated with NP-impairment, while current CD4 and plasma HIV RNA were not. This cumulative evidence suggests that in the HAART era, brain injury is relatively independent of current immune status and plasma viral load, whereas NP impairment is associated with past histories of more severe immuno-suppression. The fact that we were able to replicate this finding in a very different setting from where these results

were initially demonstrated, gives further weight to the importance of historical (versus current) measures of disease status in predicting NP outcomes in the HAART era.

We were able to detect a modest rate of NP impairment among asymptomatic or mildly symptomatic HIV+ participants, whereas the five country study by Maj et al, (1994) found impairment mostly in their symptomatic groups. This difference may be due to differences in ascertainment methods (e.g., different definitions of NP impairment; use of demographically corrected norms). In the U.S. a number of studies have found increased rates of NP impairment in asymptomatic HIV+ groups. In a review of the latter studies, White et al, (1995) reported a median of 31% NP impairment prevalence among medically asymptomatic HIV+ groups; this is consistent with the 29% prevalence rate that we observed in the non-AIDS FPDs in China.

Many published reports from Western cohorts have analyzed NP data in mixed cohorts of treated and untreated volunteers (e.g., Sevigny et al, 2004). This mixture of potentially disparate groups may have accounted for the weakening of the associations between NP impairment and other biological indicators, such as HIV RNA levels, that have been observed in “post-HAART” cohorts. In addition, we found that treated HIV+ individuals in comparison to untreated HIV+ individuals were more likely to be globally impaired (45% vs. 26%, $p < .005$) and, among those who are impaired, have worse performance (mean GDS 1.1 vs. 0.82, $P = .02$). The possible explanations for this observation include that treated individuals were also more likely to have AIDS as compared to untreated individuals (75% vs. 30%, $p < .001$) and that those treated with neurotoxic dideoxynucleoside reverse transcriptase inhibitors (dNRTIs) tended towards having worse global NP performance when compared to those who did not (mean Global Deficit Score 0.61 vs. 0.36; , $p = .07$).

In addition, the variability of regimens was restricted compared to HIV+ cohorts in Western studies. Only seven different antiretrovirals were reported, with 103 HIV+ participants reporting use of non-nucleoside reverse transcriptase inhibitors (NNRTIs; efavirenz, nevirapine) and 97 reporting use of dideoxynucleoside reverse transcriptase inhibitors (dNRTIs; stavudine and didanosine). Only four individuals reported use of a protease inhibitor (atazanavir (3), nelfinavir (1)). The most common regimen was stavudine-didanosine-nevirapine, reported by 69 HIV+ participants. Lastly, only 16% of treated individuals were on the most neuroeffective regimen ($CPE \geq 2$; see Letendre et al., 2008 for additional details on this cut-off) precluding further analysis.

Our screening for HCV infection in this study found a high prevalence of such infection among FPDs. Unlike the situation with HIV infection, however, being HCV+ was not related to the number of reported former plasma donations (12.3 ± 24.1 for uninfected group vs. 16.2 ± 24.5 for HCV mono-infected group; $p = .33$). The reason for this is unclear. Although we cannot be certain that HCV infection occurred in the same manner as HIV infection (i.e., in the course of plasma donations), two recent surveys in Shanxi province suggest that prior blood donation was a major source of both types of infection (Qian et al, 2005, 2006). Specifically, the latter authors found that: (1) HCV seroprevalence was 27.7% among FPDs in Shanxi, versus only 2.5% in non-FPDs; and (2) co-infection with HCV was seen in the large majority (85%) of HIV infected participants.

We found a small to medium NP effect size among HCV mono-infected individuals in Anhui. This too is in agreement with the current literature in the U.S., which has demonstrated mild neurocognitive impairment in about 30% of HCV+ individuals with mild liver disease, independently of substance use and other co-morbid factors such as depression and fatigue (Forton et al, 2004). Importantly, in our study the combination of AIDS and HCV was associated with the highest rate of NP-impairment (i.e., 50%). This evidence of

additive HIV/HCV effects is in accordance with reports in the U.S., which have shown worse neurocognitive deficits in co-infected individuals as compared to both HIV and HCV mono-infection individuals (Ryan et al, 2004; Cherner et al, 2005). However, in the latter U.S. studies, HCV infection was associated with histories of comorbid methamphetamine use disorders, whereas HIV infection was not. The current findings are more clearly interpretable in the absence of drug abuse comorbidity.

In reliably detecting an HCV effect on NP performance, we nevertheless found that the pattern of NP-impairment was different in several ways from HANDs. Specifically, it appeared that individuals with HCV mono-infection were less likely to show deficits on tests of processing speed, attention/working memory and verbal fluency. This should be interpreted with caution, however, given the rather small size of the HCV mono-infected group in the current study ($n=51$). Additional research with larger HCV mono-infected samples is needed to better establish the prevalence and nature of NP impairments associated with HCV infection among Chinese FPDs. Such research also should examine whether NP impairment is related to active HCV viral replication and/or indices of liver disease, as such findings could have relevance to future clinical care (medical screening, and establishing treatment priorities) within this population.

Our HIV+ cohort in Anhui had lower rates of psychiatric comorbidity than is typically seen in HIV+ groups in Western countries (less current and lifetime substance use disorders and MDD; Atkinson et al, 2008; Bing et al, 2001). Regarding substance use, lifetime alcohol use disorders were not associated with higher rate of NP impairment. Less than 2% of both the overall cohort met criteria for current MDD. Although a somewhat higher prevalence of prior lifetime MDD was seen among HIV mono-infected and co-infected participants (14% vs. 5.0% for controls), this too was lower than what has been reported in U.S. HIV+ cohorts (about 30%) and was unrelated to NP impairment. Similar to what is seen in Western countries, our Chinese HIV+ groups had a modest increase in depressed mood (BDI-II). The size of the association between current depressive symptoms and NP functioning, however, was clinically trivial (shared variance of less than 3%). This is consistent with similar cross-sectional and longitudinal findings from the U.S. (Goggin et al, 1997; Carter et al, 2003; Cysique et al, 2007b), and argues against the possibility that depression occurring in the context of HIV infection is causing the NP impairment. Indeed, the opposite may be the case: some increase in depressed mood may occur in response to awareness of reduced neurocognitive functioning.

As expected, we found associations between NP-impairment and self reports of cognitive complaints as well as decrease independence in IADLs. This finding is in agreement with what has been reported in U.S. cohorts (Heaton et al, 2004a), and demonstrates that NP-impairment has negative effects on daily functioning, even in a non-urban context where most individuals are farmers. The increased cognitive complaints in HIV+ individuals may reflect the fact that these individuals were at least partially aware that some cognitive difficulties could be related to their HIV infection. However, it should be noted that individuals with HCV at the time of testing were not aware of their HCV status. With this in mind, we observed that NP-impaired co-infected individuals reported the worst rates of decline in everyday functioning, as well as more cognitive complaints suggesting an additive effect of the illness.

Lastly, although a repeated finding in the U.S. is that HIV-related NP impairment has been associated with reduced employment (Heaton et al, 1994, 2004a), this was not seen in the current Chinese cohort. Despite the fact that the NP-impaired FPDs tended to be aware of having some cognitive difficulties, they remained active in their work duties. Possible explanations for these different employment outcomes between the U.S. and rural China

include: (1) cognitive impairment may have less impact on farming activities in China than on urban jobs in the U.S.; (2) our Chinese participants were mostly self employed, whereas NP impaired people in the U.S. are more likely to be identified by supervisors as having problems; and (3) disability income is more readily available in the U.S., whereas in rural China there is a greater need to keep working.

In summary, we find that the prevalence of HANDs in a cohort of Chinese participants infected through plasma donation is comparable to prevalence of HANDs reported in Western settings. These data underscore that neurocognitive ascertainment methods validated for HIV research in the West can be used in international settings if care is taken to assure their cultural appropriateness, examiners are properly trained, and suitable comparison groups are used. More broadly, the results indicate that HAND is likely to be a substantial problem in the developing world, emphasizing the importance of its early detection and continued efforts to develop treatments that target the CNS effects of HIV.

Acknowledgments

This study was supported by the NIMH grant 5 R01 MH073433-04 (Dr. Heaton, PI).

The HIV Neurobehavioral Research Center (HNRC) is supported by Center award MH 62512 from NIMH.

The authors would like to thank Fuyang city CDC and Psychiatric Hospital for providing staff support and the examiners for the study.

References

- Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE. Updated research nosology for HIV-associated neurocognitive disorders. *Neurology* 2007;69:1789–1799. [PubMed: 17914061]
- Atkinson JH, Heaton RK, Patterson TL, Wolfson T, Deutsch R, Brown SJ, Summers J, Sciollo A, Gutierrez R, Ellis RJ, Abramson I, Hesselink JR, McCutchan JA, Grant I. Two-year prospective study of major depressive disorder in HIV-infected men. *J Affect Disord* 2008;108(3):225–234. [PubMed: 18045694]
- Beck AT, Steer RA, Ball R, Ranieri W. Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. *J Pers Assess* 1996b;67:588–597. [PubMed: 8991972]
- Beck, AT.; Steer, RA.; Brown, GK. Manual for the Beck Depression Inventory-II. TX: Psychological Corporation: San Antonio; 1996a.
- Bing EG, Burnam MA, Longshore D, Fleishman JA, Sherbourne CD, London AS, Turner BJ, Eggen F, Beckman R, Vitiello B, Morton SC, Orlando M, Bozzette SA, Ortiz-Barron L, Shapiro M. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. *Arch Gen Psychiatry* 2001;58:721–728. [PubMed: 11483137]
- Carey CL, Woods SP, Gonzalez R, Conover E, Marcotte TD, Grant I, Heaton RK. Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. *J Clin Exp Neuropsychol* 2004;26:307–319. [PubMed: 15512922]
- Carter SL, Rourke SB, Murji S, Shore D, Rourke BP. Cognitive complaints, depression, medical symptoms, and their association with neuropsychological functioning in HIV infection: a structural equation model analysis. *Neuropsychology* 2003;17:410–419. [PubMed: 12959507]
- Chelune, G.; Heaton, R.; Lehman, R. Neuropsychological and personality correlates of patient's complaints of disability. In: Tarter, R.; Goldstein, G., editors. *Advances in Clinical Neuropsychology*. New York: New York Plenum Press; 1986. p. 95-126.
- Cherner M, Letendre S, Heaton RK, Durelle J, Marquie-Beck J, Gragg B, Grant I. Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine. *Neurology* 2005;64:1343–1347. [PubMed: 15851720]

- Clifford DB, Mitike MT, Mekonnen Y, Zhang J, Zenebe G, Melaku Z, Zewde A, Gessesse N, Wolday D, Messele T, Teshome M, Evans S. Neurological evaluation of untreated human immunodeficiency virus infected adults in Ethiopia. *J Neurovirol* 2007;13:67–72. [PubMed: 17454450]
- Cohen J. HIV/AIDS in China: an unsafe practice turned blood donors into victims. *Science* 2004;304:1438–1439. [PubMed: 15178781]
- Cysique LA, Deutsch R, Atkinson JH, Young C, Marcotte TD, Dawson L, Grant I, Heaton RK. Incident major depression does not affect neuropsychological functioning in HIV-infected men. *J Int Neuropsychol Soc* 2007b;13:1–11. [PubMed: 17166298]
- Cysique LA, Jin H, Franklin DR, Morgan EE, Shi C, Yu X, Wu Z, Taylor MJ, Marcotte TD, Letendre S, Ake C, Grant I, Heaton RK. Neurobehavioral effects of HIV-1 infection in China and the United States: A pilot study. *J Int Neuropsychol Soc* 2007a;13:781–790. [PubMed: 17697409]
- Cysique LA, Maruff P, Brew BJ. Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. *Neurology* 2006;66:1447–1450. [PubMed: 16682686]
- Ellis RJ, Deutsch R, Heaton RK, Marcotte TD, McCutchan JA, Nelson JA, Abramson I, Thal LJ, Atkinson JH, Wallace MR, Grant I. San Diego HIV Neurobehavioral Research Center Group. Neurocognitive impairment is an independent risk factor for death in HIV infection. *Arch Neurol* 1997;54:416–424. [PubMed: 9109743]
- First, MB.; Spitzer, RL.; Gibbon, M.; Williams, JB. Structured clinical interview for DSM-IV Axis I disorders. New York: Biometrics Research Department; 1996.
- Forton DM, Thomas HC, Taylor-Robinson SD. Central nervous system involvement in hepatitis C virus infection. *Metab Brain Dis* 2004;19:383–391. [PubMed: 15554429]
- Goggin KJ, Zisook S, Heaton RK, Atkinson HJ, Marshall S, McCutchan JA, Chandler JL, Grant I. Neuropsychological performance of HIV-1 infected men with major depression. *J Int Neuropsychol Soc* 1997;3:457–464. [PubMed: 9322405]
- Heaton R, Grant I, Butters N, White DA, Kirson D, Atkinson HJ, McCutchan JA, Taylor M, Kelly MD, Ellis RJ, Wolfson T, Velin RA, Marcotte TD, Hesselink JR, Jernigan TL, Chandler J, Wallace M, Abramson I. The HNRC 500-Neuropsychology of HIV infection at different disease stages. *J Int Neuropsychol Soc* 1995;1:231–251. [PubMed: 9375218]
- Heaton R, Marcotte TD, Rivera Mindt M, Sadek J, Moore D, Bentley H, McCutchan AJ, Reicks C, Grant I. The impact of HIV-associated neuropsychological impairment on everyday functioning. *J Int Neuropsychol Soc* 2004a;10:317–331. [PubMed: 15147590]
- Heaton, R.; Miller, W.; Taylor, MJ.; Grant, I. Revised Comprehensive Norms for an Expanded Halstead Reitan Battery: Demographically Adjusted Neuropsychological Norms for African American and Caucasian Adults. Lutz, FL: Psychological Assessment Resources; 2004b.
- Heaton RK, Velin RA, McCutchan JA, Gulevich SJ, Atkinson JH, Wallace MR, Godfrey HP, Kirson DA, Grant I. Neuropsychological impairment in human immunodeficiency virus-infection: implications for employment. HNRC Group. HIV Neurobehavioral Research Center. *Psychosom Med* 1994;56:8–17. [PubMed: 8197319]
- Hinkin CH, Hardy DJ, Mason KI, Castellon SA, Durvasula RS, Lam MN, Stefaniak M. Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. *AIDS* 2004;18 Suppl 1:S19–S25. [PubMed: 15075494]
- Kessler RC, Abelson J, Demler O, Escobar JI, Gibbon M, Guyer ME, Howes MJ, Jin R, Vega WA, Walters EE, Wang P, Zaslavsky A, Zheng H. Clinical calibration of DSM-IV diagnoses in the World Mental Health (WMH) version of the World Health Organization (WHO) Composite International Diagnostic Interview (WMHCIDI). *Int J Methods Psychiatr Res* 2004b;13:122–139. [PubMed: 15297907]
- Kessler RC, Ustun TB. The World Mental Health (WMH) Survey Initiative Version of the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI). *Int J Methods Psychiatr Res* 2004a;13:93–121. [PubMed: 15297906]
- Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Morgello S, Simpson D, Grant I, Ellis RJ. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. *Arch Neurol* 2008;65:65–70. [PubMed: 18195140]

- Letendre SL, McCutchan JA, Childers ME, Woods SP, Lazzaretto D, Heaton RK, Grant I, Ellis RJ. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. *Ann Neurol* 2004;56:416–423. [PubMed: 15349869]
- Maj M, Janssen R, Starace F, Zaudig M, Satz P, Sughondhabirom B, Luabeya MA, Riedel R, Ndeti D, Calil HM, et al. WHO Neuropsychiatric AIDS study, cross-sectional phase I. Study design and psychiatric findings. *Arch Gen Psychiatry* 1994a;51:39–49. [PubMed: 8279928]
- Maj M, Satz P, Janssen R, Zaudig M, Starace F, D'Elia L, Sughondhabirom B, Mussa M, Naber D, Ndeti D, et al. WHO Neuropsychiatric AIDS study, cross-sectional phase II. Neuropsychological and neurological findings. *Arch Gen Psychiatry* 1994b;51(1):51–61. [PubMed: 8279929]
- Marcotte TD, Lazzaretto D, Scott JC, Roberts E, Woods SP, Letendre S. Visual attention deficits are associated with driving accidents in cognitively-impaired HIV-infected individuals. *J Clin Exp Neuropsychol* 2006;28:13–28. [PubMed: 16448973]
- Mayeux R, Stern Y, Tang MX, Todak G, Marder K, Sano M, Richards M, Stein Z, Ehrhardt A, Gorman J. Mortality risks in gay men with human immunodeficiency virus infection and cognitive impairment. *Neurology* 1993;43:176–182. [PubMed: 8093809]
- Qian HZ, Vermund SH, Kaslow RA, Coffey CS, Chamot E, Yang Z, Qiao X, Zhang Y, Shi X, Jiang Y, Shao Y, Wang N. Co-infection with HIV and hepatitis C virus in former plasma/blood donors: challenge for patient care in rural China. *AIDS* 2006;20:1429–1435. [PubMed: 16791018]
- Qian HZ, Yang Z, Shi X, Gao J, Xu C, Wang L, Zhou K, Cui Y, Zheng X, Wu Z, Lu F, Lai S, Vermund SH, Shao Y, Wang N. Hepatitis C virus infection in former commercial plasma/blood donors in rural Shanxi Province, China: the China Integrated Programs for Research on AIDS. *J Infect Dis* 2005;192:1694–1700. [PubMed: 16235166]
- Riedel D, Ghate M, Nene M, Paranjape R, Mehendale S, Bollinger R, Sacktor N, McArthur J, Nath A. Screening for human immunodeficiency virus (HIV) dementia in an HIV clade C-infected population in India. *J Neurovirol* 2006;12:34–38. [PubMed: 16595372]
- Robertson KR, Nakasujja N, Wong M, Musisi S, Katabira E, Parsons TD, Ronald A, Sacktor N. Pattern of neuropsychological performance among HIV positive patients in Uganda. *BMC Neurol* 2007;7:8. [PubMed: 17411437]
- Royston P, Altman DG. Regression using fractional polynomials of continuous covariates: parsimonious parametric modeling. *J Royal Statistical Soc (Series C, Applied Statistics)* 1994;43:429–467.
- Ryan EL, Morgello S, Isaacs K, Naseer M, Gerits P. Neuropsychiatric impact of hepatitis C on advanced HIV. *Neurology* 2004;62:957–962. [PubMed: 15037699]
- Sacktor N, Nakasujja N, Skolasky R, Robertson K, Wong M, Musisi S, Ronald A, Katabira E. Antiretroviral therapy improves cognitive impairment in HIV+ individuals in sub-Saharan Africa. *Neurology* 2006;67:311–314. [PubMed: 16864825]
- Sacktor NC, Wong M, Nakasujja N, Skolasky RL, Selnes OA, Musisi S, Robertson K, McArthur JC, Ronald A, Katabira E. The International HIV Dementia Scale: a new rapid screening test for HIV dementia. *AIDS* 2005;19:1367–1374. [PubMed: 16103767]
- Sevigny JJ, Albert SM, McDermott MP, McArthur JC, Sacktor N, Conant K, Schifitto G, Selnes OA, Stern Y, McClernon DR, Palumbo D, Kieburtz K, Riggs G, Cohen B, Epstein LG, Marder K. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. *Neurology* 2004;63:2084–2090. [PubMed: 15596754]
- Sinha S, Satishchandra P. Nervous system involvement in asymptomatic HIV seropositive individuals: a cognitive and electrophysiological study. *Neurol India* 2003;51:466–469. [PubMed: 14742923]
- State Council AIDS working Committee Office, United Nations Theme Group on HIV/AIDS in China. A Joint Assessment of HIV/AIDS Prevention, Treatment, and Care in China 2007 <<http://www.undp.org.cn/downloads/otherlocal/HIV/20080104.pdf>>. 2007 Dec.
- Tozzi V, Balestra P, Bellagamba R, Corpolongo A, Salvatori MF, Visco-Comandini U, Vlassi C, Giulianelli M, Galgani S, Antinori A, Narciso P. Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. *J Acquir Immune Defic Syndr* 2007;45:174–182. [PubMed: 17356465]

- UNAIDS (2006). AIDS epidemic update
<http://data.unaids.org/pub/EpiReport/2006/05-Asia_2006_EpiUpdate_eng.pdf>. 2007 Dec.
- White DA, Heaton R, Monsch AU. Neuropsychological studies of asymptomatic human immunodeficiency virus-type 1 infected individuals. *J Int Neuropsychol Soc* 1995;1:304–315. [PubMed: 9375225]
- Wong MH, Robertson K, Nakasujja N, Skolasky R, Musisi S, Katabira E, McArthur JC, Ronald A, Sacktor N. Frequency of and risk factors for HIV dementia in an HIV clinic in sub-Saharan Africa. *Neurology* 2007;68:350–355. [PubMed: 17261681]
- Woods SP, Rippeth JD, Frol AB, Levy JK, Ryan E, Soukup VM, Hinkin CH, Lazzaretto D, Cherner M, Marcotte TD, Gelman BB, Morgello S, Singer EJ, Grant I, Heaton RK. Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV. *J Clin Exp Neuropsychol* 2004;26:759–778. [PubMed: 15370374]
- Yepthomi T, Paul R, Vallabhaneni S, Kumarasamy N, Tate DF, Solomon S, Flanigan T. Neurocognitive consequences of HIV in southern India: a preliminary study of clade C virus. *J Int Neuropsychol Soc* 2006;12:424–430. [PubMed: 16903135]
- Zhao M, Du J, Lu GH, Wang QY, Xu H, Zhu M, McCoy CB. HIV sexual risk behaviors among injection drug users in Shanghai. *Drug Alcohol Depend* 2006;82 Suppl 1:S43–S47. [PubMed: 16769445]

Figure 1. Effect sizes on ability domains (Main domain T-scores) and the total test battery (Global Mean T-scores) for infected groups as compared to 141 controls

SIP: Speed Information Processing

WM: Working Memory

Extended demographic characteristics of Controls, HIV mono-infected and HCV mono-infected and co-infected- groups

Table1

	Controls (n=141)	HIV mono- infected (n =108)	HCV mono- infected (n = 51)	HIV/HCV co- infected (n = 93)	Comparisons*
Age (years)	40.47 (6.20)	40.88 (6.42)	40.17 (6.70)	39.52 (6.21)	ns
Education (years)	5.80 (2.08)	5.49 (2.24)	5.60 (2.17)	5.43 (2.36)	ns
Gender % Male ¹	63.8%	66.7%	49.0%	53.7%	.07
Speaks Fuyang dialect	100.0%	100.0%	100.0%	100.0%	ns
Speaks Mandarin	12.7%	19.4%	11.7%	7.5%	ns
Han Ethnicity	99.3%	99.1%	100%	100%	ns
Grew up in rural area	100%	99.1%	100%	98.9%	ns
Resides in rural area	100%	100%	100%	98.9%	ns
Engaged in Farming	91.5%	90.6%	93.9%	86.5%	ns
Number of family members in home	5.1 (1.2)	4.1 (1.4)	5.4 (1.3)	5.2 (1.3)	ns
Currently married ²	96.5%	86.1%	94.1%	92.4%	.03
Widowed ³	3.5%	13.9%	5.9%	7.6%	.03
Number of plasma donations ⁴	12.3 (24.1)	48.6 (77.9)	16.2 (24.5)	57.3 (113.3)	<.0001

ns: non significant

* One-way Anova or overall Chi-Square comparison as appropriate

¹ HIV mono-infected > HCV + only (p=.04)

² HIV mono-infected < Controls (p=.003)

³ HIV mono-infected > Controls (p=.003)

⁴ HIV/HCV Co-infected > Controls (p<.0001); HIV mono-infected > Controls (p=.0002)

Table 2

Clinical and laboratory characteristics in the HIV mono-infected and co-infected groups

	HIV mono-infected (n=108)	HIV/HCV co-infected (n = 93)	p
Current CD4 count	321 (IQR 194–433)	350 (IQR 187–498)	ns
Nadir CD4 count	199 (IQR 150–315)	258 (IQR 164–383)	ns
Plasma HIV viral load in 132 detectable ¹	4.2 (0.8)	3.9 (0.8)	.03
HIV RNA % detectable	31%	39%	ns
Duration of known HIV seropositivity in months (SD)	152 (24)	132 (55)	.002
% AIDS	65.7%	45.1%	.004
CDC stages %			
A1	4%	11%	-
A2	18%	35%	-
A3	28%	14%	-
B1	1%	0%	-
B2	11%	8.5%	-
B3	26%	13%	-
C2	2%	5.5%	-
C3	10%	13%	-
On ARV drugs (%)	64%	48%	.03
Type of ART regimen among treated ²			
HAART (≥3 drugs)	84%	93%	ns
Dual-therapy	13%	5%	-
Monotherapy	3%	2%	-
ARV treatment duration in months (SD)	97.5 (60.3)	96.9 (53.7)	ns
CNS Penetration-Effectiveness (CPE) Ranks ³	1.56 (0.46)	1.46 (0.26)	ns
Self-reported adherence as “always”	98.5%	97%	ns

ns: non significant

NB: 8 individuals (6 HIV– and 2HIV+) did not have available blood tests and therefore no HCV status ARV: antiretroviral.

¹ NucliSens EasyQ HIV-1 from bioMérieux Easy Q assay uses real-time NASBA amplification and molecular beacon detection technology and has a range of 50 to 3 million IU(copies)/mL.

² Comparisons was conducted for HAART versus non HAART.

³ See Letendre et al., 2008 for more details in the computation of the CPE Ranks.

Table 3

Raw scores and effect sizes on individual NP test measures

	Controls (n=141)	HIV mono- infected (n=108)	HCV mono- infected (n=51)	HIV/HCV co- infected (n=93)
	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)
Executive Function				
Color Trails II (time seconds)	112.75 (30.94)	132.39 (40.48) ^b	128.78 (47.80) ^a	129.43 (49.02) ^a
WCST (Preservative errors)	15.95 (8.48)	15.15 (7.69)	16.18 (9.60)	16.33 (9.13)
Category Test (errors)	64.94 (22.84)	72.00 (27.88) ^a	67.42 (28.01)	73.92 (27.77) ^a
Verbal Fluency				
Animal fluency (total correct)	13.39 (3.25)	12.37 (3.28) ^a	12.88 (3.64)	11.90 (2.98) ^a
Action fluency (total correct)	7.72 (2.69)	6.91 (2.63) ^a	7.10 (3.54) ^a	6.78 (2.95) ^a
Attention/WM				
PASAT-50 (total correct)	28.26 (9.36)	24.80 (9.37) ^a	26.24 (10.01) ^a	24.32 (9.57) ^b
WMS-III Spatial Span	14.23 (3.39)	13.56 (3.38) ^a	13.67 (3.30)	12.58 (3.19) ^b
Learning				
HVLT-R Learning (total 3 trials)	18.45 (4.45)	17.35 (5.10) ^a	16.57 (5.57) ^a	15.63 (5.17) ^b
BVMT-R Learning (total correct)	16.67 (6.74)	13.27 (6.92) ^b	14.53 (7.70) ^a	13.51 (7.14) ^a
Memory				
HVLT-R Delayed Recall (total correct)	6.48 (2.20)	5.69 (2.43) ^a	5.51 (2.50) ^a	5.47 (2.33) ^a
BVMT-R Delayed Recall (total correct)	7.65 (2.81)	6.05 (3.07) ^b	6.67 (3.41) ^a	5.98 (3.03) ^b
Motor				
Grooved Pegboard DH (time seconds)	77.18 (15.40)	85.01 (21.31) ^a	83.59 (20.59) ^a	84.24 (28.33) ^a
Grooved Pegboard NDH (time seconds)	80.48 (18.64)	89.18 (21.14) ^a	89.39 (26.22) ^b	88.60 (29.37) ^a
SIP				
WAIS-III Digit Symbol (total correct)	41.73 (12.80)	33.44 (11.40) ^b	41.06 (14.95)	37.03 (12.92) ^a
WAIS-III Symbol Search (total correct)	18.30 (7.29)	14.11 (6.28) ^b	17.90 (6.88)	14.38 (7.12) ^b
Trail Making Test A (time seconds)	59.08 (16.82)	66.96 (18.94) ^a	65.04 (21.00) ^a	66.87 (19.39) ^a
Color Trails I (time seconds)	58.15 (17.43)	68.97 (23.77) ^b	65.98 (21.77) ^a	64.42 (21.49) ^a
Stroop color (total completed in 90s)	45.90 (12.83)	41.35 (13.58) ^a	44.94 (13.84)	38.75 (11.45) ^b

Note: Six HIV- and two HIV+ participants did not give blood samples, so their HCV status is unknown. Thus data are not included here.

NB: 3 missing values across all the data-set (WCST and one for Category test 1 participant.& and Category test for another participant).

SIP: Speed of Information Processing, WM: Working Memory, WCST: Wisconsin Card Sorting Test, HVLT-R: Hopkins Verbal Learning Test –Revised, BVMT-R: Benton Visual Retention Test-Revised).

^a small effect size (d=.20-.49).

b medium effect size ($d=.50-.79$).

Cognitive complaints, IADL dependence and employment in controls, HIV mono-infected, HCV mono-infected and co-infected groups

Table 4

	Controls (n=141)	HIV mono- infected (n=108)	HCV mono- infected (n = 51)	HIV/HCV co- infected (n = 93)	
	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)	P
Cognitive complaints (PAOFI) ¹	2.9 (3.9)	4.4 (4.7)	5.0 (5.7)	6.2 (7.0)	<.0001
Decrease IADL dependence ²	0.08 (0.6)	0.23 (0.83)	0.3 (1.1)	0.76 (1.7)	<.0001
Currently unemployed (%) ³	4.96%	24.07%	1.96%	18.28%	<.0001
Months worked in the last year ³	7.3 (2.9)	4.6 (3.3)	8.0 (3.2)	5.7 (3.5)	<.0001

Mean comparisons with Dunnett's Method, control group as a reference.

¹ Co-infected different from controls (p <.0001); HCV mono-infected and HIV mono-infected show trends from controls (p = .05; p=.07).

² Co-infected different from controls (p <.0001).

³ HIV mono-infected different from controls (p <.0001); co-infected different from controls (p =.001).